In this study, we observed that BBR alleviated Con A–induced AIH by altering the gut microbiota, inhibiting lipopolysaccharide (LPS)/toll-like receptor 4 (TLR4)/NF-κB signaling, and modulating the regulatory T cell (Treg)/Th17 balance. The gene discussed is TLR4; the disease is autoimmune hepatitis.